Effects of Allogeneic Bone Marrow Transplantation on Recipient Bone Mineral Density: A Prospective Study

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 3 A, 2000, Pages 344-351

  Kashyap, Ashwin ^a   Kandeel, Fouad ^a   Yamauchi, Dave ^a   Palmer, Joycelynne M ^a   Niland, Joyce C ^a   Molina, Arturo ^a   Fung, Henry ^a   Bhatia, Ravi ^a   Krishnan, Amrita ^a   Nademanee, Auayporn ^a   O'Donnell, Margaret R ^a   Parker, Pablo ^a   Rodriguez, Roberto ^a   Snyder, David ^a   Spielberger, Ricardo ^a   Stein, Anthony ^a   Nadler, Jerry ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; Bone mineral density; Leukemia; Lymphoma; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; MINERAL;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD DISEASE; BONE; BONE DENSITY; BONE MARROW TRANSPLANTATION; CHEMISTRY; COHORT ANALYSIS; FEMALE; HIP; HUMAN; LUMBAR VERTEBRA; MALE; METABOLIC BONE DISEASE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OSTEOPOROSIS; PATHOLOGY; PHOTON ABSORPTIOMETRY; PROSPECTIVE STUDY; RACE; RISK FACTOR;

ABSORPTIOMETRY, PHOTON; ADULT; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE MARROW TRANSPLANTATION; COHORT STUDIES; COMBINED MODALITY THERAPY; CONTINENTAL POPULATION GROUPS; FEMALE; HEMATOLOGIC NEOPLASMS; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; MINERALS; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; OSTEOPOROSIS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033654775     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70061-9     Document Type: Article

References (32)

1. Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999.
2. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet. 1993;341:797-801.
3. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;322:305-311.
4. Eastell R, Wahner HW. Methods for measuring bone mineral density. Bone. 1990;7:81-83.
5. Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practice. Br Med J. 1995;310:1507-1510.
6. Kauppila M, Irjala K, Koskinen P, et al. Bone mineral density after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:885-889.
7. Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood. 1993;82:2920-2928.
8. Bensinger W, Buckner CD. Preparative regimens. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999: 123-124.
9. Sniecinski I, O'Donnell MR. Hemolytic complications of hematopoietic transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999:674-684.
10. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993;17:1225-1230.
11. O'Donnell MR, Schmidt GM, Tegtmeier B, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol. 1994;12:827-834.
12. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida crusei infection among patients with bone marrow transplantation and neutropenic treated prophylaxis with fluconazole. N Engl J Med. 1991;325:1274-1277.
13. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. City of Hope-Stanford-Syntex CMV Study Group: a randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med. 1991;324:1005-1011.
14. Katz IA, Epstein S. Post-transplantation bone disease. J Bone Miner Res. 1992;7:123-126.
15. Bhatia S, Ramsay NK, Weisdorf D, Griffiths H, Robison LL. Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant. 1998;1:87-90.
16. Kelly PJ, Atkinson K, Ward RL, Sambrook PN, Biggs JC, Eisman JA. Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation. 1990;5:881-883.
17. Bizot P, Witvoet J, Sedel L. Avascular necrosis of the femoral head after allogeneic bone marrow transplantation: a retrospective study of 27 consecutive THAs with a minimum two-year follow-up. J Bone Joint Surg Br. 1996;6:878-883.
18. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res. 1999;3:342-350.
19. Välimaki MJ, Kinnunen K, Volin L, et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant. 1999;23:355-361.
20. Castaneda S, Carmona L, Carvajal I, Arranz R, Diaz A, Garcia-Vadillo A. Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int. 1997;4:343-347.
21. Socie G, Selimi F, Sedel L, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol. 1994;3:624-628.
22. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societé Française de Greffe de Moelle (SFGM). Br J Haematol. 1997;4:865-870.
23. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990;6:733-738.
24. Atkinson K, Cohen M, Biggs J. Avascular necrosis of the femoral head secondary to corticosteroid therapy for graft-versus-host disease after marrow transplantation: effective therapy with hip arthroplasty. Bone Marrow Transplant. 1987;4:421-426.
25. Russell JA, Blahey WB, Stuart TA, Edward G, Card RT. Avascular necrosis of bone in bone marrow transplant patients. Med Pediatr Oncol. 1989;2:140-143.
26. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988;123:2571-2577.
27. Bourbigot B, Moal MC, Cleder J. Bone histology in renal transplant patients receiving cyclosporin. Lancet. 1988;i:1048-1049.
28. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-364.
29. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res. 1996;11:1-7.
30. Castelo-Branco C, Rovira M, Pons F, et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas. 1996;3:307-312.
31. Braith RW, Mills RM Jr, Welsch MA, Keller JW, Pollock ML. Resistance exercise training restores bone mineral density in heart transplant recipients. J Am Coll Cardiol. 1996;28:1471-1477.
32. Shane E, Rodino MA, McMAhon DJ, et al. Prevention of bone loss after heart transplantation with antiabsorptive therapy: a pilot study. J Heart Lung Transplant 1998;17:1089-1096.